CILAPAM LS 5 MG TAB
₹165.00
Cilapam LS 5 Tablet is a combination of Escitalopram (5 mg), a selective serotonin reuptake inhibitor (SSRI), and Clonazepam (0.25 mg), a benzodiazepine. This combination is used to treat anxiety disorders and related conditions.
Description
Cilapam LS 5 Tablet is a combination medication used in the treatment of anxiety disorders. It contains:
-
Escitalopram Oxalate (5 mg): An SSRI that increases serotonin levels in the brain, helping to improve mood and reduce anxiety.
-
Clonazepam (0.25 mg): A benzodiazepine that works by calming the brain and nerves, providing relief from anxiety symptoms.
This combination is particularly beneficial for patients whose anxiety symptoms are not adequately controlled with a single medication. By addressing multiple mechanisms, it helps in reducing the symptoms of excessive anxiety and worry.
Uses:
-
Generalized Anxiety Disorder (GAD)
-
Panic Disorder
-
Social Anxiety Disorder
Side Effects:
Common side effects include:
-
Escitalopram: Nausea, fatigue, dry mouth, dizziness, increased sweating, sexual dysfunction.
-
Clonazepam: Drowsiness, dizziness, tiredness, uncoordinated body movements, memory impairment.
If you experience any severe or persistent side effects, consult your doctor promptly.
Dosage and Administration:
-
Dosage: As prescribed by your healthcare provider, based on individual health conditions.
-
Administration: Take the tablet once daily, preferably at the same time each day, with or without food.
-
Note: Do not crush or chew the tablet; swallow it whole.
Precautions:
-
Alcohol: Avoid consumption as it may enhance certain side effects like dizziness and drowsiness.
-
Pregnancy: Consult your doctor before use during pregnancy.
-
Breastfeeding: Consult your doctor before use during breastfeeding.
-
Driving: May cause drowsiness or dizziness. Avoid driving if you experience these symptoms.
-
Liver/Kidney Disease: Use with caution in patients with liver or kidney disease. Dose adjustment may be needed.









Reviews
There are no reviews yet.